+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel Focus on cardiac safety



Multicenter randomized phase III trial of epirubicin plus paclitaxel vs epirubicin followed by paclitaxel Focus on cardiac safety



Breast Cancer Research & Treatment 76(Supplement 1): S89




(PDF emailed within 1 workday: $29.90)

Accession: 035349911

Download citation: RISBibTeXText


Related references

Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety. British Journal of Cancer 91(1): 45-49, July 5, 2004

A randomized multicenter phase III trial comparing epirubicin and paclitaxel with epirubicin and cyclophosphamide as first line chemotherapy in patients with metastatic breast cancer. Breast Cancer Research & Treatment 57(1): 84, 1999

PREPARE trial a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa. 2011

PREPARE trial a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel +/- darbepoetin alfa in primary. 2011

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosis. Annals of Oncology 22(9): 1999-2006, 2011

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer--results at the time of surgery. Annals of Oncology 22(9): 1988-1998, 2011

PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery. Journal of Clinical Oncology 26(15_suppl): 517-517, 2016

Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: a Central European Cooperative Oncology Group International, multicenter, prospective, randomized phase III trial. Journal of Clinical Oncology 23(7): 1401-1408, 2005

Weekly cisplatin - epirubicin - paclitaxel with G-CSF support vs triweekly epirubicin-paclitaxel in advanced breast cancer A SICOG phase III trial. European Journal of Cancer 37(Supplement 6): S151-S152, 2001

Longitudinal serum results of HER-2/neu, EGFR and CA2729 in a randomized trial comparing dose-intense, biweekly epirubicin followed by paclitaxel to 3-weekly epirubicin plus cyclophosphamide followed by paclitaxel for adjuvant therapy of nodal-positive breast cancer. Breast Cancer Research & Treatment 82(Supplement 1): S130, 2003

5-Fluorouracil, epirubicin and cyclophosphamide versus epirubicin and paclitaxel in node-positive early breast cancer: a phase-III randomized GONO-MIG5 trial. Breast Cancer Research and Treatment 155(1): 117-126, 2016

Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: Vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study. Breast 12(3): 208-211, 2003

Gemcitabine, epirubicin and paclitaxel vs 5-fluorouracil, epirubicin and cyclophosphamide as first-line treatment in metastatic breast cancer Interim toxicity analysis of a randomised, multicenter phase III trial of the Central European Cooperative Oncology Group. European Journal of Cancer 37(Supplement 6): S194, 2001

Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic breast cancer The French experience. Seminars in Oncology 24(1 SUPPL 3): 8-12, 1997

Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience. Seminars in Oncology 24(1 Suppl 3): S8-12, 1997